Low Testosterone and Obesity: No Single Treatment Leads
A new comparison of treatments for obesity-related low testosterone finds different strengths for different outcomes. The review does not identify one approach that consistently wins on hormone levels, sexual function, body composition, and metabolic health. For patients, it argues against choosing treatment from a single laboratory result.
Twenty-three Trials, Several Treatment Approaches
The Journal of Sexual Medicine published the network meta-analysis on September 7, 2026. Researchers included 23 randomized trials involving 1,899 participants with obesity-related functional hypogonadism. The comparison covered structured lifestyle therapy, testosterone replacement, therapies intended to restore endogenous testosterone, GLP-1-based treatment, and selected combinations.
Testosterone plus structured lifestyle therapy had the largest estimated increase in total testosterone. The combination also improved erectile-function questionnaire scores by an average of 1.29 points against usual care or placebo. No approach consistently led across all outcomes. The authors rated confidence in many comparisons low or very low because the trials and their follow-up differed.
Why Functional Hypogonadism Needs Its Own Assessment
The European Association of Urology distinguishes potentially reversible contributors to low testosterone from disorders involving the testes or the signaling pathway that controls them. Its guidance recommends considering symptoms, repeated morning measurements, health conditions, and medicines before selecting treatment. In men with obesity, addressing weight and related health problems can form part of that assessment and care.
That does not mean every man with obesity should wait indefinitely for help with sexual symptoms. It means the plan needs to identify what the clinician thinks drives the deficiency and which goals each intervention serves. A man with testicular disease may need a different approach from someone whose hormone changes accompany a substantial change in weight.
A Smaller Trial Highlights a Fertility Difference
A separate randomized study in 25 men with obesity, type 2 diabetes, and functional hypogonadism compared semaglutide with testosterone treatment over 24 weeks. Investigators reported improvements in sperm morphology and testosterone with semaglutide. The small, open-label study cannot establish that a weight-loss medicine treats every fertility problem or replaces hormone therapy for all causes of deficiency.
It does show why fertility deserves a separate question when comparing treatments. A higher testosterone measurement is not the same endpoint as sperm quality or the ability to conceive. The EAU advises against testosterone therapy in men who currently wish to father children. Bring that priority into the conversation before choosing a treatment, rather than after starting it.
Weight Management Is More Than a Prescription Choice
NIDDK describes obesity treatment as a combination of approaches that can include nutrition, physical activity, behavior changes, medicines, and surgery when appropriate. Medicines support a broader plan rather than replace it. The choice depends on weight-related health problems, preferences, previous treatment, and the risks and benefits of the available options.
A patient may need support with sleep, activity limitations, eating patterns, or a medicine that affects weight. Those issues can change what a realistic plan looks like. Ask which part of the care plan aims to reduce weight, which aims to address a hormone deficiency, and which aims to improve erection function. Progress in one area does not guarantee progress in every other area.
What a Network Comparison Can and Cannot Rank
A network meta-analysis can compare treatments through a mixture of direct and indirect evidence. That allows a broader comparison than a single trial, but it also depends on how well the populations and treatment conditions align. A numerical ranking can look more certain than the evidence behind it.
Here, the authors explicitly caution against a definitive treatment hierarchy. The largest estimated hormone increase does not establish the best treatment for a man who mainly wants improved sexual function, wants children, or has concerns about adverse effects. A useful consultation connects the chosen outcome to the treatment decision.
Do Not Let One Outcome Stand in for Another
A larger hormone increase, a smaller waist measurement, and a better erection score describe different results. A treatment might improve one without leading the comparison on another. The review's mixed findings make it useful to ask which outcome matters most for the decision in front of you.
For example, a man planning a pregnancy needs a conversation that includes fertility, while someone with troublesome ED needs a way to judge sexual function. A ranking based only on total testosterone cannot resolve either decision. Agree on the relevant goals before using a laboratory change to describe the treatment as successful.
Questions for Follow-up
Ask what would count as a meaningful response for you: a change in symptoms, a hormone result, weight-related health, or several of those. Discuss when to review progress and what would justify changing the plan. Bring previous measurements so the clinician can compare like with like.
The low testosterone section covers assessment, and the ED overview describes treatment options for erection symptoms that may need attention alongside metabolic care.

Comments